在轻度化学中风中ProUrokinase的推理和设计 (PUMICE):一个多中心,前性,随机化,开放标签,盲目的终点受控试验
相关实验视频
Updated: Jul 1, 2026

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.9K
Yunyun Xiong1,2,3, Manjun Hao1, Yuesong Pan2
1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Stroke and vascular neurology
|January 31, 2024
概括
这项研究评估了复合人体前激酶 (rhPro-UK) 治疗急性轻度缺血性中风. 它旨在确定使用rhPro-UK的血栓溶解是否能在症状出现后4.5小时内改善结果.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性缺血性中风需要及时干预.
- 复合人体前激酶 (rhPro-UK) 是一种新型的等离子体激活剂.
- 轻度缺血性中风往往得到标准的医疗治疗,没有血栓溶解.
研究的目的:
- 与标准治疗相比,评估rhPro-UK的疗效和安全性.
- 在急性轻度缺血性中风患者中研究血栓溶解的益处.
- 提供rhPro-UK在症状出现后4.5小时内使用的证据.
主要方法:
- 一个多中心,前性,随机化,开放标签,盲目的终点试验 (NCT05507645).
- 在4.5小时内招募急性缺血性中风和NIHSS得分≤5的患者.
- 随机分配给静脉注射rhPro-UK (35毫克) 或标准的医疗治疗,随着90天的随访.
主要成果:
- 主要结局:优异的功能结局 (mRS ≤1在90天).
- 二次结果包括mRS分布,早期的神经改善,巴特尔指数,生活质量和ADLs.
- 通过症状性内出血,死亡率,出血事件和不良事件来评估安全性.
结论:
- 这一III期试验将确定急性轻度缺血性中风的血栓溶解益处.
- 结果可能支持rhPro-UK作为轻度缺血性中风的治疗选择.
- 证据将指导对急性轻度缺血性中风患者的rhPro-UK的临床决定.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

